CUTANEOUS MELANOMA
Clinical trials for CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for fighting advanced melanoma in the brain
Disease control Recruiting nowThis early-stage trial is testing new drug combinations for people with melanoma skin cancer that has spread to the brain. It aims to see if these drugs can shrink brain tumors in patients whose cancer has worsened despite previous immunotherapy. The study will test two different…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for melanoma patients who Don't respond to standard treatments
Disease control Recruiting nowThis trial is testing new combinations of immunotherapy drugs given before surgery for patients with advanced melanoma that can be surgically removed. The study focuses on patients who are predicted to respond poorly to standard immunotherapy or whose melanoma has returned despit…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Blood test guides fight to stop deadly skin Cancer's return
Disease control Recruiting nowThis study is for people with high-risk melanoma who have had surgery to remove their cancer. Researchers are testing if a combination of two immunotherapy drugs works better than the current standard single drug at preventing the cancer from returning. They will use a special bl…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Radioactive 'Seeker' drug targets advanced cancers in first human test
Disease control Recruiting nowThis is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments…
Matched conditions: CUTANEOUS MELANOMA
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New Immune-Boosting drug enters first human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new drug called MBS8 for people with advanced solid tumors that have stopped responding to standard treatments. The trial will test the drug alone and in combination with an existing immunotherapy in specific groups of melan…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First human test of Dual-Attack cancer therapy begins
Disease control Recruiting nowThis is a first-in-human study to test the safety and early effectiveness of a two-part treatment called IMA203 combined with mRNA-4203. It is for people with advanced skin cancer (melanoma) or a rare soft-tissue cancer (synovial sarcoma) that has spread and no longer responds to…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:19 UTC
-
New hope for Tough-to-Treat skin cancer
Disease control Recruiting nowThis study is testing a new oral drug, LNS8801, for people with advanced melanoma that has spread and no longer responds to standard immunotherapies. Researchers want to see if LNS8801, taken alone or combined with the drug pembrolizumab, can stop or slow cancer growth better tha…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New antibody drug enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis is the first study in people to test a new drug called AU-007 for advanced cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug shows early signs of helping. It will be tested alone and in combination with other…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Aulos Bioscience, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
New targeted drug trial seeks to control Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new drug called IDE196, both alone and combined with other drugs, for people with advanced cancers that have specific genetic changes (GNAQ/11 mutations or PRKC fusions). The main goals are to find safe doses and see if the treatments can shrink tumors. It…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
AI vs. cancer: new test aims to predict which drugs will work
Diagnosis Recruiting nowThis study aims to develop and test a new diagnostic tool that uses artificial intelligence (AI) to analyze small pieces of a patient's tumor. The goal is to predict whether a patient will respond to certain immunotherapy cancer drugs before they start treatment. Researchers will…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: Elephas • Aim: Diagnosis
Last updated Apr 02, 2026 14:57 UTC
-
Could a simple cream ease the sting of cancer mapping?
Symptom relief Recruiting nowThis study is testing whether a numbing cream called EMLA can reduce the brief pain patients feel from injections during a lymph node mapping procedure for skin cancer. About 100 adults with melanoma, Merkel cell, or squamous cell skin cancer will be randomly assigned to use eith…
Matched conditions: CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC
-
Tracking the hidden toll of cancer treatment
Knowledge-focused Recruiting nowThis study aims to better understand the side effects that melanoma patients experience while receiving immunotherapy treatments. Researchers will follow 300 patients over time to track their symptoms, identify patterns, and learn what factors might make side effects worse. The g…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Apr 03, 2026 21:10 UTC
-
Can your mindset and habits fight skin cancer? major study investigates
Knowledge-focused Recruiting nowThis study aims to understand how factors like mental health, diet, exercise, and social support are linked to quality of life and health outcomes for people with melanoma. Researchers will enroll up to 5,000 participants to complete surveys about their lifestyle and well-being a…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:43 UTC
-
Researchers map hidden cancer risk in families
Knowledge-focused Recruiting nowThis study aims to better understand the BAP1 hereditary cancer syndrome, which increases risk for several cancers including eye melanoma, skin melanoma, and mesothelioma. Researchers will study 500 participants with personal or family history of these cancers to identify pattern…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: Mohamed Abdel-Rahman • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:41 UTC
-
Is your job giving you skin cancer? italian study investigates sun exposure risk
Knowledge-focused Recruiting nowThis study aims to understand if working outdoors increases the risk of developing specific types of skin cancer (melanoma) linked to long-term sun exposure. Researchers in Modena, Italy, will interview 300 patients who have had a skin biopsy. They will compare the work and sun e…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: University of Modena and Reggio Emilia • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:48 UTC